Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

Study ID
NCT00108875

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcinoma.

More informations

Trial Starting Date

Apr 30,2003

Requirements

Gender All
Minimum age 19 Years
Maximum age 90 Years

Enrollement Limit